SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors react to a recent SEC filing regarding executive change-of-control agreements, which the community is widely interpreting as a strategic precursor to a potential buyout. The stock is seeing significant volatility fueled by extreme short-squeeze conditions, including surging borrow fees and a large trapped short position ahead of an anticipated clinical readout for its flagship oncology asset.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense volatility and heavy selling pressure as investors grapple with a structural decline, a surprise CFO transition, and deep uncertainty heading into earnings. The community remains sharply divided, with some betting on a generational value play backed by iconic brand status, while others fear a continued downtrap driven by persistent competition and weak guidance.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the market anticipates key catalysts, including the upcoming release of five-year open-label extension data for its Duchenne muscular dystrophy candidate and a pivotal court hearing regarding its commercial distribution rights. The community is actively discussing the potential for a broad label expansion and the strategic path toward independent commercialization as they monitor legal developments and progress toward an August PDUFA date.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing intense volatility and bearish sentiment as the community debates the sustainability of its debt-fueled Bitcoin acquisition strategy amid a prolonged market downturn. Investors are sharply divided, with many expressing concern over potential liquidity risks and dividend obligations while others view the current price action as a generational buying opportunity.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing high volatility as investors weigh fundamental performance against technical pressure, with the community actively debating whether the stock is a bargain at current levels or trapped in a sustained structural decline. Many traders are focused on the stock's struggle to reclaim key support levels while speculating on the potential impact of share buybacks and a possible rotation from high-flying AI names back into established tech leaders.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is experiencing significant volatility and social media attention as retail investors mobilize to drive a short squeeze, hoping to capitalize on high short interest and undervaluation narratives. The community is actively debating the sustainability of the price action, with many encouraging others to hold their shares and resist pressure from short sellers.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros shares are trending sharply lower as investors react to a negative CHMP opinion on narsoplimab in the EU, though the community remains focused on the companys intent to appeal through an expert panel. While some express frustration with management communication, many long-term shareholders are actively discussing the U.S. FDA-approved product's potential and the upcoming path to regulatory reversal as a core value proposition.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending as investors bet on a potential short squeeze, fueled by high short interest and aggressive company-led share buybacks. The community is actively debating the stock's fundamental turnaround and the impact of the newly appointed COO, with many traders drawing parallels to other high-profile squeeze plays.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending due to the announcement of a $6 billion share repurchase program, which has sparked investor interest and fueled discussions regarding the company's valuation and long-term outlook. Community sentiment is mixed, with some traders viewing the buyback as a sign of management's confidence and an opportunity for value, while others remain skeptical, focusing on broader automotive market headwinds and the stock's recent performance.

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

Transmedics Group is trending as investors react to a significant post-earnings volatility, with the community actively debating whether the decline is a temporary margin squeeze driven by aggressive infrastructure expansion or a signal of structural revenue concerns. While short-term sentiment remains cautious due to technical selling and broader sector headwinds, long-term investors are highlighting strong flight data and the company's expanding market share as core pillars of the ongoing growth thesis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Full Transcript: Belite Bio Q1 2026 Earnings Call

Belite Bio Enters Oversold Territory (BLTE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Belite Bio (BLTE) Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Nathan Mata Sells 1,000 Shares of Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of Belite Bio stock in a transaction on Tuesday, May 5th. The stock was sold at an average price...

Belite Bio (BLTE) Projected to Post Quarterly Earnings on Tuesday

Belite Bio (NASDAQ:BLTE) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-belite-bio-inc-stock...

Insider Selling: Belite Bio (NASDAQ:BLTE) Insider Sells 1,000 Shares of Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of the firm's stock in a transaction on Wednesday, April 29th. The shares were sold at an average...

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the firm...

Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of the company's stock in a transaction dated Wednesday, April 29th. The shares were sold at an...

Belite Bio (NASDAQ:BLTE) Insider Sells $162,640.00 in Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was sold at an average...

Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference

Belite Bio (NASDAQ:BLTE) highlighted progress for its lead drug candidate tinlarebant during the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference, outlining late-stage clinical...

Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Belite Bio Inc - ADR

Bearish Sentiment

$UBER only

$INTC only

Both $UBER and $INTC

Neither

Nancy Pelosi recently disclosed trades in both Uber ($UBER) and Intel ($INTC) - are you following her into either? Cast your vote below.

Are you following Nancy Pelosi into her latest trades - Uber ($UBER) and Intel ($INTC)?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.77	--	--	N/A
Q1 '26	-$0.63	-$0.34	46.45%	BEAT
Q4 '25	-$0.55	-$0.38	30.43%	BEAT
Q3 '25	-$0.49	-$0.65	-33.33%	MISSED
Q2 '25	-$0.41	-$0.50	-21.95%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

BLTEBelite Bio Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest BLTE News